Shots:

• The approval is based on data assessing bioequivalence and AEs associated with IM administration vs SC administration of Plegridy in healthy volunteers
• Result: The data showed that participants receiving therapy through IM experienced fewer injection site reactions (14.4 vs 32.1 %)- safety profiles were similar. The frequency of injection site reactions and AEs were comparable in participants who were dosed with IM followed by SC- compared to SC followed by IM
• The approval expands the offerings to the individuals with RMS- providing treatment option combining safety & efficacy to optimize the treatment experience with a reduction in injection site reactions

 ­ Ref: Biogen  | Image: Biogen